Contribution of bi-allelic germline MUTYH mutations to early-onset and familial colorectal cancer and to low number of adenomatous polyps: case-series and literature review by Hes, F.J. et al.
ORIGINAL ARTICLE
Contribution of bi-allelic germline MUTYH mutations
to early-onset and familial colorectal cancer and to low number
of adenomatous polyps: case-series and literature review
A. P. Knopperts • M. Nielsen • R. C. Niessen • C. M. J. Tops • B. Jorritsma •
J. Varkevisser • J. Wijnen • C. L. E. Siezen • R. C. Heine-Bro ¨ring •
H. J. van Kranen • Y. J. Vos • H. Westers • E. Kampman • R. H. Sijmons •
F. J. Hes
Published online: 25 September 2012
 Springer Science+Business Media B.V. 2012
Abstract In the absence of a polyposis phenotype, colo-
rectal cancer (CRC) patients referred for genetic testing
because of early-onset disease and/or a positive family his-
tory, typically undergo testing for molecular signs of Lynch
syndromeintheirtumors.Intheabsenceofthesesigns,DNA
testing for germline mutations associated with other known
tumor syndromes is usually not performed. However, a few
studies inlargeseries ofCRCpatients suggestthatinasmall
percentage of CRC cases, bi-allelic MUTYH germline
mutations can be found in the absence of the MUTYH-
associatedpolyposisphenotype.Thishasnotbeenstudiedin
the Dutch population. Therefore, we analyzed the MUTYH
gene for mutations in 89 patients with microsatellite-low or
stable CRC cancer diagnosed before the age of 40 years or
otherwise meeting the Bethesda criteria, all of them without
apolyposisphenotype.Inaddition,westudiedaseriesof693
non-CRCpatients with 1–13 adenomatous colorectal polyps
for the MUTYH hotspot mutations Y179C, G396D and
P405L. No bi-allelic MUTYH mutations were observed. Our
data suggest that the contribution of bi-allelic MUTYH
mutations to the development of CRC in Dutch non-polyp-
osispatientsthatmeetclinicalgeneticreferralcriteria,andto
the development of low number of colorectal adenomas in
non-CRC patients, is likely to be low.
Keywords Colorectal cancer  Adenomatous polyps 
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Introduction
Colorectal cancer (CRC) is one of the most frequent solid
tumors worldwide. In the Netherlands, it is the second most
common type of cancer for women and third most common
type for men, with more than 12,000 new cases reported in
2009 [1]. Although most CRC cases are sporadic,
approximately 15–25 % of all CRC patients have a positive
family history [2, 3], indicating genetic predisposition to
CRC. The two best-characterized types of hereditary CRC
are Lynch syndrome and familial adenomatous polyposis
(FAP). These syndromes are autosomal dominant inherited
disorders that account for approximately 3 % and 0.1–1 %
of CRC diagnoses [4]. In addition to FAP, other polyposis
syndromes have been recognized, including MUTYH
associated Polyposis (MAP) accounting for 0.5–1 % of
CRC diagnosis [5, 6] and Peutz–Jeghers syndrome, juve-
nile polyposis and other rare syndromes, each contributing
to a small part of familial colorectal cancer. Unfortunately,
for most of the remaining familial CRC cases, which
usually do not present with a polyposis phenotype, under-
lying genetic factors are still unclear [7].
Typically, after referral for clinical genetic studies of
colorectal cancer and in the absence of a polyposis
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patients and families meeting particular clinical criteria are
studied for signs indicative of Lynch syndrome. In the past,
the Amsterdam criteria were used for selection, however,
nowadays, the revised Bethesda criteria [8] are more
commonly used. Characteristic features of Lynch syn-
drome include an increased risk for developing CRC, on
average at a younger age, a predisposition for extracolonic
malignancies including endometrial, ovarian and gastric
carcinoma, and a positive family history [9]. After tumor
testing for Lynch syndrome–associated features, micro-
satellite instability and/or loss of staining for mismatch
repair (MMR) gene coded proteins, patients suspected of
having Lynch syndrome are subsequently tested for
germline MMR gene mutations. Patients and families with
tumors that are not indicative of Lynch syndrome, and
without a polyposis phenotype, are subsequently not rou-
tinely offered DNA testing for tumor syndrome genes and
usually counseled on the basis of their family history with
respect to cancer risks and appropriate surveillance pro-
grams. Additional genes for hereditary CRC may be
identiﬁed in the future and testing of those genes may
become part of the diagnostic strategy. However, it is
possible that known tumor syndrome genes may present
with phenotypes, including non-polyposis CRC, that are
not traditionally associated with germline defects in those
genes. Although these genes are not routinely tested in
early-onset and/or familial CRC, such testing might be
warranted. MUTYH is one of the genes to be considered
testing in this setting.
Although bi-allelic MUTYH mutations are typically
associated with the adenomatous polyposis syndrome
known as MUTYH-associated polyposis (MAP) [10], CRC
in the absence of a polyposis phenotype has been observed
in a few patients with germline bi-allelic MUTYH muta-
tions in large (population based) CRC series [11–17]. For
this reason we have searched for the presence of bi-allelic
MUTYH mutations in two independent cohorts of Dutch
CRC patients that had been referred for genetic testing and
counseling. In addition, we have studied the frequency of
such mutations in a large Dutch cohort of non-CRC
patients with low number of adenomatous polyps because
this frequency in our population was unknown and there-
fore the potential clinical use of MUTYH analysis in this
type of patients difﬁcult to assess.
Materials and methods
Groningen CRC study population
Patients diagnosed with colorectal cancer before the age of
40 years, referred after January 1st 2005 to the department
of Genetics of the University Medical Center Groningen
for genetic study, were included in the study, irrespective
of their family history. Only one patient per family was
included. Patients with more than 20 polyps, and those with
tumor microsatellite instability and/or loss of immunohis-
tochemical staining for MMR proteins (methods published
previously [18–20] were excluded. In total, 47 CRC
patients were selected (16 men and 31 women; see Table 1
for other characteristics). DNA was isolated from periph-
eral blood lymphocytes using standard techniques. DNA
testing was approved by the institute’s medical ethical
review board.
Leiden CRC study population
From the clinical diagnostic and research registries at the
department of Clinical and Human Genetics of the Leiden
University Medical Center, we selected CRC patients
meeting Amsterdam and/or Bethesda criteria with MSI-low
or stable CRC, normal IHC and less than 20 polyps.
Presence of MMR gene mutations, a polyposis phenotype,
lack of details on personal medical and/or family medical
history were exclusion criteria. Only one patient per family
was included. In total, 42 CRC patients were selected for
DNA analysis (20 men and 22 women; see Table 1 for
other characteristics). DNA was isolated from peripheral
blood lymphocytes using standard techniques. DNA testing
was approved by the institute’s medical ethical review
board.
Wageningen colorectal polyp study population
DNA was obtained from 668 healthy controls and 693
individuals previously gathered in an endoscopy-based
case control study, which focused on gene-environment
interactions and colorectal adenoma risk. In this study,
participants were recruited among those undergoing
endoscopy of the large bowel in ten outpatient clinics in
the Netherlands between June 1997 and June 2002. The
colorectal adenoma cases include both men and women,
from 18 years of age up to age 75 at diagnosis, with no
family history of CRC and with no history of CRC, partial
colorectal resection or inﬂammatory bowel disease.
Colonoscopy was performed for follow-up after previously
detected colorectal adenomas or gastrointestinal com-
plaints. Cases were selected for the presence of at least one
histologically conﬁrmed colorectal adenomatous polyp
(see Table 1). The age at which polyps was detected in this
population is shown in Fig. 1. DNA was isolated from
peripheral blood lymphocytes using standard techniques
[21]. The Medical Ethics Committee of Radboud
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approved the study.
Groningen and Leiden MUTYH analysis
Mutation scanning of the coding region of the MUTYH
gene was performed by denaturing gradient gel electro-
phoresis (DGGE) combined with direct sequencing of PCR
fragments showing aberrant gel patterns in DGGE analysis,
as published previously [20, 22]. Denaturing gradient gel
electrophoresis has been widely used and has been shown
to be a sensitive mutation detection method [23].
Wageningen population MUTYH analysis
At the National Institute for Public Health and the Envi-
ronment (RIVM) MUTYH analysis of the hotspots Y179C,
G396D and P405L in the controls and polyp patients was
performed using the Pyrosequencing
TM technique (http://
www.pyrosequencing.com/)[ 24] as reported previously
[25]. In Caucasian populations, a bi-allelic status for the
hot spot mutations p.Y179C and/or p.G396D is reported in
up to 70 % of MAP patients. Furthermore, 90 % of the
western MAP population carries at least one of these
mutations [26]. P405L is the third hotspot mutation in the
Dutch population [22].
Results
Details of the results are shown in Table 1. Mutations are
reported referring to the MUTYH Genomic sequence:
NG_008189.1 (http://www.ncbi.nlm.nih.gov/gene/4595)
[27]. Mutations Y179C, G396D and P405L have previ-
ously been published as Y165C, G382D and P391L,
respectively. In the Groningen, Leiden and Wageningen
series, no bi-allelic MUTYH mutations were identiﬁed.
Mono-allelic mutations were observed in 0/47, 2/42
Table 1 Study population characteristics and MUTYH analysis results
Population Selection criteria CRC
characteristics
Polyps Bethesda Amsterdam
II
MUTYH
Groningen:
Dutch,
white
Caucasian
N = 47
CRC\40 yrs,
MSS tumor and normal
tumor MMR protein
staining
\20 polyps
Mean age:
33.9 yrs
Range: 22–39 yrs
6 patients with
adenomatous polyps
(range: 1–8 polyps)
47/47
(100 %)
8/47
(17.0 %)
Full gene analyzed
Mut/mut; 0/47
Mut/wt: 0/47
WT/WT:
47/47(100 %)
Leiden:
Dutch, white
Caucasian
N = 42
CRC
Bethesda criteria positive
\20 polyps
MSS of MSI-L
Normal MMR protein
IHC
Mean age 52.2 yrs
(Range: 29–71)
11 patients with
adenomatous polyps
(range 1–4 polyps)
42/42
(100 %)
30/42
(71.4 %)
Full gene analyzed
Mut/mut: 0/42
Mut/wt: 2/42 (4.8 %;
1 9 Y179C and
1 9 G396D)*
Wt/wt: 40/42 (95.2 %)
Wageningen:
Dutch,
white
Caucasian
N = 693
One or more adenomatous
polyps
Colonoscopy perfomed
because of clinical
complaints or follow-up
after previous polyp
No previous history of
CRC or other
CR disease
Not
applicable
100 % had between 1 and
13 adenomatous polyps:
1–2 polyps in 69.7 %;
3–4 in 16.2 %;
5–6 in 8.2 %;
7–8 in 3.8 % and 8–13
polyps in 2.1 % of
cases.
Ages at diagnosis
35–75 years (see Fig. 1)
0/693 0/693 3 hotspot mutations
analyzed: Y179C;
G396D and P405L
Mut/mut 0/693
Mut/wt: 15/693
(2.1 %;
4 9 Y179C,
11 9 G396D)*
CR colorectal, CRC colorectal cancer, IHC immunohistochemical staining for the Lynch syndrome-associated MMR gene-coded proteins, MMR
DNA mismatch repair genes, MSI microsatellite instability, MSS microsatellite stable, MSI-L microsatellite instability- low, Mut MUTYH gene
germline mutation, Wt wild type MUTYH allele, Yrs age in years
* not signiﬁcantly different from the heterozygote frequency of 2.2 % in 668 Dutch controls (p[0.1)
Fig. 1 Age distribution of adenomatous colorectal polyps detected in
693 individuals from the Wageningen study
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123(4.8 %) and 15/693 (2.1 %) cases in the Groningen, Leiden
and Wageningen series, respectively. These frequencies
were not signiﬁcantly different from the 15/668 (2.2 %)
frequency observed in the controls (p = 0.1 and 0.85,
respectively, Fisher exact). This heterozygote frequency
corresponds to published population frequencies of 1–2 %
[11–13].
Discussion
Our ﬁndings of zero bi-allelic MUTYH germline mutations
suggest that the contribution of these bi-allelic mutations to
the development of low number of adenomatous polyps in
non-CRC patients, or to the development of early-onset and
familial colorectal cancer in Dutch patients, is likely to be
small. In our health care insurance setting, a cut-off of
10 % chance of ﬁnding a germline mutation is traditionally
used to decide for or against testing for a particular gene.
Although the size of our clinical genetics study population
was limited, the chance of observing zero bi-allelic muta-
tions in a sample of 89 individuals from a population with
an 10 % or higher proportion of such bi-allelic mutations is
extremely small (8.5*10
-5 or smaller). Still, because of the
autosomal recessive nature of bi-allelic MUTYH mutations,
we might have observed a higher frequency of mutations in
CRC cases selected for negative family history or those
with affected siblings only. On the other hand, although the
issue is still under debate, mono-allelic MUTYH mutations
may cause a small increase in CRC risk [28] and parents of
patients with MUTYH bi-allelic mutations more frequently
have CRC than can be expected in the general population
[29]. Therefore, MUTYH mutations could also be expected
in families with CRC in multiple generations. The pub-
lished studies on bi-allelic MUTYH mutations observed in
in non-polyposis colorectal cancer patients are summarized
in Table 2. These studies had different designs, making
comparisons difﬁcult. Bi-allelic MUTYH mutations were
identiﬁed in MSI low or stable CRC patients, ranging in
age between 31 and 48 years with zero (6 cases) or a small
number of polyps (2 cases, 3 and 12 adenomas respec-
tively) [16, 17]. However, polyp counts were unavailable
for 2 of the patients in the Riegert-Johnson series [16]. The
twelve patients with bi-allelic mutations in the Croituro
series [13] had not been preselected using MSI and/or IHC
ﬁndings. Seven of these patients had less than 10 polyps,
their ages at CRC diagnosis ranged between 35 and
66 years. In total, in four of the studies, no MSI and/or IHC
had been performed, which makes it difﬁcult to extrapolate
their ﬁndings to patients that are referred for clinical
genetic testing who are typically ﬁrst analyzed for these
tumor characteristics. Six out of 7 studies analyzed
MUTYH for hotspot mutations only. Therefore, the fre-
quency of MUTYH mutations might have been somewhat
underestimated and the same is true for our non-CRC polyp
series which because of its large size has been analyzed for
3 hotspot mutations only.
Another important ﬁnding in the reported studies is that
when bi-allelic mutations in the absence of a multiple
polyp phenotype are present, this is not limited to those
CRC cases with early-onset disease. Given the commonly
known natural history of the MAP syndrome phenotype,
which, like FAP, is associated with increasing number of
polyps with increasing age, this is a somewhat unexpected
ﬁnding. Likely environmental and other genetic factors
might explain this difference of polyp count in CRC
patients with bi-allelic MUTYH mutations. These study
ﬁndings therefore suggest that age might not be an
appropriate selection criterion for deciding when to look
for MUTYH bi-allelic mutations in CRC patients without or
with only few polyps. In our study, we might have
observed a higher frequency of bi-allelic MUTYH if later-
onset colorectal cancer cases would have been included.
However, we deliberately selected only younger age-at-
onset cases or those otherwise meeting the Bethesda cri-
teria, reﬂecting the patients typically referred for genetic
analysis.
As previously reported, certain tumor features, molec-
ular and histological might better help direct the physician,
i.e. pathologist, towards a MAP etiology of CRC. These
features include a proximal location, mucinous histotype,
increased presence of tumor inﬁltrating lymphocytes and a
speciﬁc somatic KRAS mutation (the c.34G[T in codon
12), since these were found to be relative common in MAP
related CRCs [30, 31].
Taken together, the literature and present ﬁndings sug-
gest that bi-allelic MUTYH mutations in non-polyposis
CRC patients and in non-CRC patients with low number of
adenomatous polyps are relatively rare. Given the present
costs of DNA testing, including that of testing mutation
hotspots only, and the fact that only a limited number of
gene tests per patient are covered by Dutch health care
insurance, we suggest that germline MUTYH testing should
not yet be part of the routine genetic analysis of patients
with non-polyposis colorectal cancer or of a low number of
adenomatous polyps in our country. Other countries may
face similar ﬁnancial constraints. In the meantime tumor
analysis, especially KRAS hot spot analysis, could be
implemented as a pre-screening test that helps select
patients with CRC who are eligible for MUTYH mutation
screening [31]. A more widespread use of MUTYH analysis
should, however, be considered when genetic testing
becomes more affordable, for example as part of a targeted
analysis gene panel in next generation sequencing.
46 A. P. Knopperts et al.
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